Literature DB >> 30514497

Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting.

Yuri F van der Heijden1, Fareed Abdullah2, Bruno B Andrade3, Jason R Andrews4, Devasahayam J Christopher5, Julio Croda6, Heather Ewing7, David W Haas8, Mark Hatherill9, C Robert Horsburgh10, Vidya Mave11, Helder I Nakaya12, Valeria Rolla13, Sudha Srinivasan14, Retna Indah Sugiyono15, Cesar Ugarte-Gil16, Carol Hamilton17.   

Abstract

RePORT International is a global network of research sites in India, Brazil, Indonesia, South Africa, China, and the Philippines dedicated to collaborative tuberculosis research in the context of HIV. A standardized research protocol (the Common Protocol) guides the enrollment of participants with active pulmonary tuberculosis and contacts into observational cohorts. The establishment of harmonized clinical data and bio-repositories will allow cutting-edge, large-scale advances in the understanding of tuberculosis, including identification of novel biomarkers for progression to active tuberculosis and relapse after treatment. The RePORT International infrastructure aims to support research capacity development through enabling globally-diverse collaborations. To that end, representatives from the RePORT International network sites, funding agencies, and other stakeholders gathered together in Brazil in September 2017 to present updates on relevant research findings and discuss ideas for collaboration. Presenters emphasized research involving biomarker identification for incipient tuberculosis, host immunity and pharmacogenomics, co-morbidities such as HIV and type 2 diabetes mellitus, and tuberculosis transmission in vulnerable and high-risk populations. Currently, 962 active TB participants and 670 household contacts have contributed blood, sputum, urine and microbes to in-country biorepositories. Cross-consortium collaborations have begun sharing data and specimens to analyze molecular and cytokine predictive patterns.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Biomarkers; Diabetes; HIV; Incipient tuberculosis; Pharmacogenomics; Transmission

Mesh:

Year:  2018        PMID: 30514497      PMCID: PMC6349374          DOI: 10.1016/j.tube.2018.09.009

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  74 in total

1.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

2.  Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.

Authors:  Hanneke M J Nijland; Rovina Ruslami; Janneke E Stalenhoef; Erni J Nelwan; Bachti Alisjahbana; Ron H H Nelwan; Andre J A M van der Ven; Halim Danusantoso; Rob E Aarnoutse; Reinout van Crevel
Journal:  Clin Infect Dis       Date:  2006-08-22       Impact factor: 9.079

3.  Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.

Authors:  Yi-Shin Huang; Herng-Der Chern; Wei-Juin Su; Jaw-Ching Wu; Shinn-Liang Lai; Shi-Yi Yang; Full-Young Chang; Shou-Dong Lee
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

4.  HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers.

Authors:  P Sonnenberg; J Murray; J R Glynn; S Shearer; B Kambashi; P Godfrey-Faussett
Journal:  Lancet       Date:  2001-11-17       Impact factor: 79.321

5.  Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production.

Authors:  Andre Bafica; Charles A Scanga; Charles Serhan; Fabiana Machado; Sandy White; Alan Sher; Julio Aliberti
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

6.  Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.

Authors:  Yi-Shin Huang; Herng-Der Chern; Wei-Juin Su; Jaw-Ching Wu; Shi-Chuan Chang; Chi-Huei Chiang; Full-Young Chang; Shou-Dong Lee
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

Review 7.  Tobacco and tuberculosis: a qualitative systematic review and meta-analysis.

Authors:  K Slama; C-Y Chiang; D A Enarson; K Hassmiller; A Fanning; P Gupta; C Ray
Journal:  Int J Tuberc Lung Dis       Date:  2007-10       Impact factor: 2.373

Review 8.  Pharmacogenomics of anti-TB drugs-related hepatotoxicity.

Authors:  Puspita Das Roy; Mousumi Majumder; Bidyut Roy
Journal:  Pharmacogenomics       Date:  2008-03       Impact factor: 2.533

9.  The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis.

Authors:  Bachti Alisjahbana; Edhyana Sahiratmadja; Erni J Nelwan; Anugrah Maya Purwa; Yana Ahmad; Tom H M Ottenhoff; Ronald H H Nelwan; Ida Parwati; Jos W M van der Meer; Reinout van Crevel
Journal:  Clin Infect Dis       Date:  2007-07-05       Impact factor: 9.079

Review 10.  Organic anion-transporting polypeptide (OATP) transporter family and drug disposition.

Authors:  R B Kim
Journal:  Eur J Clin Invest       Date:  2003-11       Impact factor: 4.686

View more
  2 in total

1.  Lipid mediators of inflammation and Resolution in individuals with tuberculosis and tuberculosis-Diabetes.

Authors:  Rupak Shivakoti; Jesmond Dalli; Dileep Kadam; Sanjay Gaikwad; Madhusudan Barthwal; Romain A Colas; Francesca Mazzacuva; Rahul Lokhande; Sujata Dharmshale; Renu Bharadwaj; Anju Kagal; Neeta Pradhan; Sona Deshmukh; Sachin Atre; Tushar Sahasrabudhe; Arjun Kakrani; Vandana Kulkarni; Swapnil Raskar; Nishi Suryavanshi; Sandy Chon; Akshay Gupte; Amita Gupta; Nikhil Gupte; María B Arriaga; Kiyoshi F Fukutani; Bruno B Andrade; Jonathan E Golub; Vidya Mave
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-11-11       Impact factor: 3.072

2.  Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients.

Authors:  Wen Shi; Juan Wu; Qi Tan; Chun-Mei Hu; Xia Zhang; Hong-Qiu Pan; Zhen Yang; Meng-Yu He; Min Yu; Bo Zhang; Wei-Ping Xie; Hong Wang
Journal:  Infect Drug Resist       Date:  2019-05-14       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.